<< IAN survey gives grandparents a voice in autism research community | Media outlets examine urbanization, health ahead of World Health Day >>

Read in | English | Português | 日本語 | 한국어 | 简体中文 | Русский

Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID

Published on April 7, 2010 at 3:00 AM · No Comments

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.

"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"

Poster presenter: Derrick Crook, M.D.

Saturday, April 10, 2010 3:30pm–4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2401

"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"

Poster presenter: Mark A. Miller, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2394

SOURCE Optimer Pharmaceuticals, Inc.

e9d7a39f-d401-4765-a321-4a7fe852fdb0|0|.0

Posted in: Drug Trial News | Disease/Infection News

Tags: Antibiotic, Biotechnology, Clostridium difficile, Diarrhea, Fluoroquinolone, Microbiology

Related posts

Sigma introduces CompoZr Targeted Integration Kit – mRosa26Sigma Life Science, the innovative biological products and services research business of Sigma-Aldri...
Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteriaJust like intelligence agents watching for the real terrorists threatening to attack, monitoring hea...
Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exc...
Advaxis initiates ADXS11-001 clinical trial for cervix cancerAdvaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has beg...
Econiche vaccine cited in February, 2010 issue of Scientific AmericanBioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company,...
Rimonabant appears to be very promising, especially for the treatment of patients with abdominal obesityOverweight or obese people who are stout around the waist and abdomen are particularly at high risk ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.